238 related articles for article (PubMed ID: 32392832)
1. The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor.
Astolfi A; Pantaleo MA; Indio V; Urbini M; Nannini M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392832
[TBL] [Abstract][Full Text] [Related]
2. Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST.
Urbini M; Astolfi A; Indio V; Nannini M; Schipani A; Bacalini MG; Angelini S; Ravegnini G; Calice G; Del Gaudio M; Secchiero P; Ulivi P; Gruppioni E; Pantaleo MA
Sci Rep; 2020 Nov; 10(1):19829. PubMed ID: 33199729
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
4. Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST.
Urbini M; Indio V; Tarantino G; Ravegnini G; Angelini S; Nannini M; Saponara M; Santini D; Ceccarelli C; Fiorentino M; Vincenzi B; Fumagalli E; Casali PG; Grignani G; Pession A; Ardizzoni A; Astolfi A; Pantaleo MA
Genes Chromosomes Cancer; 2019 Sep; 58(9):636-642. PubMed ID: 30887595
[TBL] [Abstract][Full Text] [Related]
5. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Ricci R; Martini M; Ravegnini G; Cenci T; Milione M; Lanza P; Pierconti F; Santini D; Angelini S; Biondi A; Rosa F; Alfieri S; Clemente G; Persiani R; Cassano A; Pantaleo MA; Larocca LM
Clin Epigenetics; 2019 Jan; 11(1):2. PubMed ID: 30616628
[TBL] [Abstract][Full Text] [Related]
6. Succinate dehydrogenase-deficient gastrointestinal stromal tumors.
Wang YM; Gu ML; Ji F
World J Gastroenterol; 2015 Feb; 21(8):2303-14. PubMed ID: 25741136
[TBL] [Abstract][Full Text] [Related]
7. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
8. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
[TBL] [Abstract][Full Text] [Related]
9. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors: molecular markers and genetic subtypes.
Barnett CM; Corless CL; Heinrich MC
Hematol Oncol Clin North Am; 2013 Oct; 27(5):871-88. PubMed ID: 24093165
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].
Kalfusová A; Kodet R
Cesk Patol; 2017; 53(4):167-173. PubMed ID: 29227120
[TBL] [Abstract][Full Text] [Related]
13. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
Flavahan WA; Drier Y; Johnstone SE; Hemming ML; Tarjan DR; Hegazi E; Shareef SJ; Javed NM; Raut CP; Eschle BK; Gokhale PC; Hornick JL; Sicinska ET; Demetri GD; Bernstein BE
Nature; 2019 Nov; 575(7781):229-233. PubMed ID: 31666694
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
[TBL] [Abstract][Full Text] [Related]
16. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
17. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
18. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).
Nannini M; Biasco G; Astolfi A; Pantaleo MA
J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252
[TBL] [Abstract][Full Text] [Related]
19. Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update.
Rubin BP; Heinrich MC
Semin Diagn Pathol; 2015 Sep; 32(5):392-9. PubMed ID: 25766843
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
